{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:29:51Z","timestamp":1792092591741,"version":"4.4.0"},"reference-count":102,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T00:00:00Z","timestamp":1442275200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2015,9,15]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Nonmotor manifestations in Parkinson's disease (PD) encompass a range of clinical features, including neuropsychiatric problems, autonomic dysfunction, sleep disorders, fatigue, and pain. Despite their importance for patients' quality of life, the evidence base for their treatment is relatively sparse. Nevertheless, the last few years have seen a number of new trials starting that specifically address nonmotor features as an outcome measure in clinical trials. Large randomized, controlled trials in the last 3 years reported improvement of psychosis with the new selective serotonin 5\u2010HT2A inverse agonist pimavanserin and of postural hypotension with the oral norepinephrine precursor droxidopa. Smaller new randomized, controlled trials support the effectiveness of Deep Brain Stimulation and opiates for pain, of rivastigmine for apathy and piribedil for apathy post\u2010DBS, group cognitive behavioral therapy for depression and\/or anxiety, continuous positive airway pressure for sleep apnea in PD and doxepin for insomnia, and of solifenacin succinate and transcutaneous tibial nerve stimulation for urinary symptoms. A number of new smaller or open trials as well as post\u2010hoc analyses of randomized, controlled trials have suggested usefulness of other treatments, and new randomized, controlled trials are currently ongoing. \u00a9 2015 International Parkinson and Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.26415","type":"journal-article","created":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T09:10:00Z","timestamp":1442308200000},"page":"1490-1504","source":"Crossref","is-referenced-by-count":83,"title":["New clinical trials for nonmotor manifestations of Parkinson's disease"],"prefix":"10.1002","volume":"30","author":[{"given":"Anette","family":"Schrag","sequence":"first","affiliation":[{"name":"Department of Clinical Neurosciences UCL Institute of Neurology London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sauerbier","sequence":"additional","affiliation":[{"name":"National Parkinson Foundation International Center of Excellence, King's College London; National Institute for Health Research (NIHR) Mental Health Biomedical Research Center and Dementia Unit at South London and Maudsley NHS Foundation Trust and King's College London, United Kingdom; Department of Basic and Clinical Neuroscience, The Maurice Wohl Clinical Neuroscience Institute, Kings College London London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kallol Ray","family":"Chaudhuri","sequence":"additional","affiliation":[{"name":"National Parkinson Foundation International Center of Excellence, King's College London; National Institute for Health Research (NIHR) Mental Health Biomedical Research Center and Dementia Unit at South London and Maudsley NHS Foundation Trust and King's College London, United Kingdom; Department of Basic and Clinical Neuroscience, The Maurice Wohl Clinical Neuroscience Institute, Kings College London London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,9,15]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.12968\/hmed.2014.75.1.18"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70068-7"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2006.05.030"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23462"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23742"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22438"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25919"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2014.12.031"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057221"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2014.10.026"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2013-000741"},{"key":"e_1_2_8_13_1","article-title":"Psychosis in Parkinson's disease: identification, prevention and treatment","author":"Levin J","journal-title":"J Neural Transm"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23884"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756285610389656"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2011.139"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62106-6"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-003533"},{"key":"e_1_2_8_19_1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/WNF.0000000000000080","article-title":"Adverse reactions to antipsychotics in Parkinson disease: an analysis of the Spanish Pharmacovigilance Database","volume":"38","author":"Lertxundi U","year":"2015","journal-title":"Clin Neuropharmacol"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.2-150.v1"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1367014"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-014-1212-4"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70106-X"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881113478282"},{"key":"e_1_2_8_25_1","first-page":"154","article-title":"Mixed effects of deep brain stimulation on depressive symptomatology in Parkinson's disease: a review of randomized clinical trials","volume":"5","author":"Gokbayrak NS","year":"2014","journal-title":"Front Neurol"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181d55f24"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2014.2472"},{"key":"e_1_2_8_28_1","article-title":"A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non\u2010demented Parkinson's disease patients","author":"Barone P","journal-title":"Eur J Neurol"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2013.02.018"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26067"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2014.02.025"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10111669"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.neuropsych.12120381"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-14-19"},{"key":"e_1_2_8_35_1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3233\/JPD-120156","article-title":"Guided self-help for the management of worry in Parkinson's disease: a pilot study","volume":"3","author":"Lawson RA","year":"2013","journal-title":"J Parkinsons Dis"},{"key":"e_1_2_8_36_1","volume-title":"Specialist rehabilitation for people with Parkinson's disease in the community: a randomized controlled trial","author":"Gage H","year":"2014"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25194"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1142\/S0192415X15500263"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.3171\/2014.4.JNS131711"},{"key":"e_1_2_8_40_1","first-page":"586378","article-title":"Effect of exercise on motor and nonmotor symptoms of Parkinson's disease","volume":"2015","author":"Dashtipour K","year":"2015","journal-title":"Parkinsons Dis"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/arclin\/acu038.51"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000644"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26208"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2014.02.009"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000050"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2013.02.018"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awq032"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awt067"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2013-306439"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26099"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000729"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318263570d"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23441"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12075"},{"key":"e_1_2_8_55_1","first-page":"131508","article-title":"Transdermal rotigotine improves sleep fragmentation in Parkinson's disease: results of the multicenter, prospective SLEEP\u2010FRAM study","volume":"2015","author":"Pagonabarraga J","year":"2015","journal-title":"Parkinsons Dis"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-2011-11037"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2013.12.016"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.752351"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0000000000000041"},{"key":"e_1_2_8_60_1","unstructured":"University of Zurich. Study of the Symptomatic Effects of Nocturnal Sodium Oxybate in Parkinson's Disease (PD-Xyrem). Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02111122?term=oxybate+parkinson&rank=1. Accessed May 17 2015."},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.5665\/sleep.3332"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2013.03.003"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756285611406166"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2012.08.010"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12179"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.52.9179"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2014-001000"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000615"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26086"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.114.04035"},{"key":"e_1_2_8_71_1","unstructured":"Philadelphia Veterans Affairs Medical Center. Treatment of Orthostatic Intolerance in Patients With Parkinson's Disease Using Midodrine. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02365012. Accessed May 17 2015."},{"key":"e_1_2_8_72_1","unstructured":"University of Zurich. Orthostatic Dysregulation and Associated Gastrointestinal Dysfunction in Parkinson's Disease\u2013Treatment. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01993680. Accessed May 17 2015."},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2015.02.025"},{"key":"e_1_2_8_74_1","doi-asserted-by":"publisher","DOI":"10.1097\/WON.0000000000000078"},{"key":"e_1_2_8_75_1","unstructured":"Sir Mortimer B. Davis - Jewish General Hospital. Fesoterodine on Urgency Episodes in Parkinson's Disease Population. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02385500. Accessed May 17 2015."},{"key":"e_1_2_8_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70287-X"},{"key":"e_1_2_8_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(06)70373-8"},{"key":"e_1_2_8_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2014.11.024"},{"key":"e_1_2_8_79_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182574f28"},{"key":"e_1_2_8_80_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2013.833605"},{"key":"e_1_2_8_81_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-013-2684-z"},{"key":"e_1_2_8_82_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12571"},{"key":"e_1_2_8_83_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2013.753056"},{"key":"e_1_2_8_84_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2015.997211"},{"key":"e_1_2_8_85_1","unstructured":"Rhythm Pharmaceuticals Inc. A Phase 2 Study to Evaluate the Safety and Efficacy of RM-131 in Patients With Parkinson's Disease & Chronic Constipation (MOVE-PD) Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01955616?term=NCT01955616&rank=1. Accessed May 17 2015."},{"key":"e_1_2_8_86_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-14-42"},{"key":"e_1_2_8_87_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182a08d00"},{"key":"e_1_2_8_88_1","unstructured":"UCB BIOSCIENCES GmbH. Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain (DOLORES). Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01744496?term=dolores+parkinson&rank=2. Accessed May 17 2015."},{"key":"e_1_2_8_89_1","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01606670?term=neupad+parkinson&rank=1. Accessed May 17 2015."},{"key":"e_1_2_8_90_1","unstructured":"Rambam Health Care Campus. Relaxation Guided Imagery for Treatment of Pain in Parkinson's Disease. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01865097. Accessed May 21 2015."},{"key":"e_1_2_8_91_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-015-7823-3"},{"key":"e_1_2_8_92_1","unstructured":"Mundipharma Research GmbH & Co KG.A randomized placebo controlled study of OXN PR for severe Parkinson's disease associated pain. Available at:www.clinicaltrials.gov\/ct2\/show\/NCT01439100. Accessed May 17 2015."},{"key":"e_1_2_8_93_1","article-title":"Prolonged-release oxycodone\/naloxone (OXN PR) is associated with treatment benefits in patients with severe Parkinson's disease (PD)-related pain: Results from a randomised, controlled trial [abstract]","volume":"30","author":"Trenkwalder C, Martinez-Martin P, Rascol O, et al.","year":"2015","journal-title":"Mov Disord"},{"key":"e_1_2_8_94_1","unstructured":"Ray Chaudhuri K. ABSTRACT MDS."},{"key":"e_1_2_8_95_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awq268"},{"key":"e_1_2_8_96_1","doi-asserted-by":"publisher","DOI":"10.1586\/ern.10.56"},{"key":"e_1_2_8_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70287-X"},{"key":"e_1_2_8_98_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23742"},{"key":"e_1_2_8_99_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0070244"},{"key":"e_1_2_8_100_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26077"},{"key":"e_1_2_8_101_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12733"},{"key":"e_1_2_8_102_1","doi-asserted-by":"publisher","DOI":"10.1038\/npjparkd.2015.13"},{"key":"e_1_2_8_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2014.10.026"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.26415","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.26415","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T11:07:40Z","timestamp":1760958460000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.26415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,15]]},"references-count":102,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,9,15]]}},"alternative-id":["10.1002\/mds.26415"],"URL":"https:\/\/doi.org\/10.1002\/mds.26415","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725788229.793510234","asserted-by":"object"}]},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,15]]}}}